HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.108.052464v1 49/9/1445    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Remy, H. Articles by Ricard, M. Search for Related Content PubMed PubMed Citation Articles by Remy, H. Articles by Ricard, M.

¹³¹I Effective Half-Life and Dosimetry in Thyroid Cancer Patients

¹ Department of Nuclear Medicine, Institut Gustave Roussy, Villejuif, France; ² Department of Health Economics, Institut Gustave Roussy, Villejuif, France; ³ Department of Medical Physics, Institut Gustave Roussy, Villejuif, France; ⁴ INSERM U 605, Institut Gustave Roussy, Villejuif, France; and ⁵ University Paris-Sud, Bicêtre, France

Correspondence: For correspondence or reprints contact: Remy Hervé, Department of Nuclear Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. E-mail: herve.remy{at}igr.fr

¹³¹I treatment in thyroid cancer patients may induce side effects, including extrathyroidal cancer and leukemia. There are still some uncertainties concerning parameters that may influence the effective half-life of ¹³¹I and the absorbed doses by extrathyroidal organs. Methods: Whole-body retention of radioiodine was measured in 254 patients, and repeated quantitative whole-body scans and measurements of the urinary excretion of ¹³¹I were performed on 30 of these patients. Results: The mean effective half-life (10.5 h) was shorter by 31%, with little difference between patients, in the 36 patients who received recombinant human thyroid-stimulating hormone than in the 218 patients who underwent thyroid hormone withdrawal (15.7 h). The residence times in the stomach and in the rest of the body were significantly shorter in patients who received recombinant human thyroid-stimulating hormone than in patients who underwent withdrawal, but the residence times were similar in the colon and bladder. Conclusion: In patients who undergo thyroid hormone withdrawal, the longer mean effective half-life is mainly due to delayed renal excretion of ¹³¹I and results in dose estimates higher than the data in report 53 of the International Commission on Radiological Protection, which were obtained from healthy, euthyroid subjects.

Key Words: ¹³¹I • effective half-life • recombinant human TSH • thyroid cancer • dosimetry

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				M. Luster, D. Handkiewicz-Junak, A. Grossi, M. Zacharin, D. Taieb, O. Cruz, A. Hitzel, J. A. Vallejo Casas, U. Mader, M. E. Dottorini, et al. Recombinant Thyrotropin Use in Children and Adolescents with Differentiated Thyroid Cancer: A Multicenter Retrospective Study J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3948 - 3953. [Abstract] [Full Text] [PDF]

				A. Frigo, A. Dardano, E. Danese, M. V. Davi, P. Moghetti, C. Colato, G. Francia, F. Bernardi, C. Traino, F. Monzani, et al. Chromosome Translocation Frequency after Radioiodine Thyroid Remnant Ablation: A Comparison between Recombinant Human Thyrotropin Stimulation and Prolonged Levothyroxine Withdrawal J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3472 - 3476. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri A Vision for the Surgical Management of Papillary Thyroid Carcinoma: Extensive Lymph Node Compartmental Dissections and Selective Use of Radioiodine J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1086 - 1088. [Full Text] [PDF]